CARM Stock — Carisma Therapeutics Inc.

Carisma Therapeutics Inc. (CARM)

Updated October 15, 2026.

CARM is a Stock. Its deepest 1-year drawdown was 99.9%.

Carisma Therapeutics is a biotechnology company developing cell therapy treatments for liver fibrosis and solid tumors, including a mesothelin-targeted CAR-Monocyte therapy in phase I clinical trials and an in vivo CAR-M cell therapy program in collaboration with Moderna. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotechnology development with a focus on cellular immunotherapy approaches.

CARM performance

Returns are updating. CARM's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 99.9%.

CARM key facts

Asset type

Stock

Asset class

Equity

Inception date

02/06/2014

Distribution frequency

None

Last close

$0.02 (as of 2026-10-15)

Market cap

$836,902

Average volume

1123.0

Ex-dividend date

03/08/2023

Payment date

03/08/2023

Payout ratio

0.0%

EPS

$7.60

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CARM risks and drawbacks

The deepest 1-year drawdown on record here is 99.9%.

Who may consider CARM — and who may not

It is a weaker fit for investors who need monthly cash flow (CARM does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CARM

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions